## conferenceseries.com

## WORLD EYE AND VISION CONGRESS

December 09-10, 2019 Dubai, UAE

One-year results of half-dose photodynamic therapy versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy

Vanchalearm Banchasakjaroen and P Jirarattanasopa

Prince of Songkla University, Thailand

**Objective:** To compare the efficacy of half-dose photodynamic Therapy (PDT) and one-third-dose PDT in treatment in chronic or recurrence Central Serous Chorioretinopathy (CSC).

**Methods:** A retrospective review of chronic or recurrence CSC patients, who were treated with half-dose or one-third dose PDT for 12 months follow-up. Best-Corrected Visual Acuity (BCVA), Central Retinal Thickness (CRT) and resolution of Subretinal Fluid (SRF) at baseline, 1, 3, 6, and 12 months post PDT were assessed.

Results: 46 eyes and 20 eyes received half-dose and one-third dose PDT, respectively. The study shows non-inferiority of the one-third-dose PDT compared with half-dose PDT in BCVA improvement  $(0.10\pm0.04 \text{ vs. } 0.17\pm0.04 \text{ LogMar}, P=0.293)$  and CRT improvement  $(125.6\pm24.6 \text{ vs. } 139.1\pm16.54 \text{ \mum}, P=0.652)$  at 12 months follow-up. The recurrence rates of SRF was significant higher in one-third-dose of PDT compared with half-dose PDT (40.0% vs. 15.2%, P=0.027) at 12 months follow-up.

**Conclusion:** One-third-dose PDT was non inferiority in BCVA and CRT improvement when compared with half-dose PDT. This study showed one-third-dose PDT was higher recurrence rate of disease.

## **Biography**

Vanchalearm Banchasakjaroen has the expectation to improve vision of the people in the world as he can. In the training program he was interested in the retinal specialist and he had the experience in treatment of central serous chorioretinopathy (CSC) in patients. He had done the research in the optimal dose of verteporfin and it is not reported. This research is to compare the efficacy of half-dose PDT and one-third-dose PDT in treatment of chronic, or recurrence CSC. He hopes this research will be making the decision of treatment in the patients with CSC.

**Notes:**